- Planned HERIZON-GEA-01 Analyses and the Doublet-vs-Triplet QuestionNew HER2+ gastric cancer data show triplet immunotherapy boosts survival and durable responses, hinting immune activation beyond HER2 targets.onclive · 2mo ago↗ source
- HERIZON-GEA-01 Efficacy Results and Interpretation of Duration of ResponseHORIZON-GA01 shows zenidatamab regimens significantly improve survival in HER2-positive gastric cancer, while PD-L1 testing differences raise key questions for treatment choice.onclive · 2mo ago↗ source
- Five-year survival with tebentafusp in previously untreated metastatic uveal melanoma in a phase 3 trial (CT029)Five-year Phase III data show tebentafusp doubles survival in metastatic uveal melanoma, with ctDNA response predicting benefit beyond imaging and progression.